A Phase 3 randomized trial has shown that finerenone, a drug previously limited to patients with type 2 diabetes and chronic kidney disease (CKD), can slow kidney decline in adults with CKD who do not have diabetes. That finding, if it holds up in regulatory review, could reshape treatment for a condition that affects an estimated 674 million people worldwide and roughly 37 million adults in the United States alone. The trial results land at a moment when kidney specialists already have a second drug class, SGLT2 inhibitors, proven across broad CKD populations, raising the question of how quickly clinicians will combine or sequence these therapies for the vast majority of patients who have been left without targeted options.
Why finerenone’s expansion beyond diabetes changes the calculus for CKD
Until now, finerenone’s evidence base rested almost entirely on two large trials in patients who had both type 2 diabetes and CKD. The FIDELIO-DKD and FIGARO-DKD studies, combined in the FIDELITY pooled analysis, demonstrated kidney and cardiovascular benefits in that specific population. The drug earned regulatory approvals on that basis. But diabetes accounts for only a fraction of all CKD cases. Hypertension, glomerular diseases, genetic conditions, and aging drive kidney damage in tens of millions of people who had no randomized evidence supporting finerenone use.
The new Phase 3 study in non-diabetic CKD, reported in the New England Journal, enrolled adults with reduced kidney function and elevated albumin in the urine but excluded those with diabetes. Investigators measured the rate of kidney function decline using the slope of estimated glomerular filtration rate, or eGFR. A slower eGFR decline means the kidneys are losing filtering capacity more gradually, which translates into delayed dialysis or transplant. For patients living with a disease that often progresses silently for years, even a modest reduction in that slope can mean additional years of kidney function and fewer complications.
Finerenone belongs to a class known as nonsteroidal mineralocorticoid receptor antagonists. By blocking the mineralocorticoid receptor, the drug aims to reduce inflammation and fibrosis in kidney tissue rather than simply lowering blood pressure. That mechanistic distinction matters because many non-diabetic CKD patients already take standard therapies such as ACE inhibitors or ARBs. The hope is that layering finerenone on top of those drugs can further slow structural damage inside the kidney, particularly in patients who continue to leak protein into the urine despite optimal blood pressure control.
One hypothesis worth tracking as researchers analyze these results further is whether finerenone’s benefit proves largest in patients with moderate albuminuria and low baseline potassium. Hyperkalemia, or elevated blood potassium, has been the drug’s primary safety concern since the diabetic CKD trials. If subgroup analyses, especially those stratified by risk categories similar to those used in the EMPA-KIDNEY trial of empagliflozin, confirm that lower-risk potassium profiles predict stronger benefit, clinicians would gain a practical tool for selecting the right patients early. Conversely, if the risk of hyperkalemia appears concentrated in specific subgroups-such as those with advanced CKD or concurrent medications that raise potassium-guidelines may recommend closer monitoring or lower starting doses in those populations.
Trial evidence and the global scale of unmet need
The new randomized trial in non-diabetic CKD is the first large study to test finerenone outside the diabetic population using a kidney function endpoint as its main outcome. Its primary endpoint, the chronic eGFR slope, directly measures how fast kidney function erodes over time. That design mirrors the approach regulators have increasingly accepted as a valid surrogate for hard outcomes like kidney failure, particularly when follow-up time is limited and event rates are relatively low. Secondary endpoints in the study included composite measures of kidney failure, sustained eGFR decline, and cardiovascular events, which will help contextualize how changes in eGFR slope translate into clinical benefit.
Separately, a randomized clinical trial tested finerenone specifically in patients whose CKD stems from glomerular diseases, a category that includes conditions such as IgA nephropathy and focal segmental glomerulosclerosis. That study, described in a JAMA report and registered as NCT05047263, adds another layer of evidence for non-diabetic use. In that trial, investigators focused on changes in proteinuria and kidney function over time, aiming to determine whether finerenone can slow progression in diseases where immune-mediated injury rather than diabetes or hypertension is the primary driver. Together, these trials signal a deliberate effort to build the case for finerenone across the full spectrum of CKD causes.
The numbers behind that spectrum are staggering. The World Health Organization estimates that about 674 million people worldwide have chronic kidney disease. In the United States, surveillance data from the Centers for Disease Control and Prevention indicate that roughly 14 percent of adults-around 37 million people-are living with CKD, based on National Health and Nutrition Examination Survey sampling extrapolated to the 2023 U.S. population. Most of those patients do not have diabetes as the primary driver of their kidney disease, which means they sat outside finerenone’s approved indication until this new evidence emerged. Many are diagnosed late, when kidney function is already severely impaired and options to delay dialysis are limited.
The EMPA-KIDNEY trial, a separate landmark study published in the New England Journal of Medicine, already showed that the SGLT2 inhibitor empagliflozin reduced kidney disease progression across a broad CKD population that included many patients without diabetes. That trial established a new standard of care by demonstrating benefits on both kidney and cardiovascular outcomes. Finerenone works through a different mechanism, blocking the mineralocorticoid receptor rather than sodium-glucose co-transport. The practical consequence is that physicians may soon have two distinct drug classes, each supported by randomized evidence, available for non-diabetic CKD patients. Whether combining them produces additive benefit or compounding side effects is a question no completed trial has yet answered, and future research will need to explore optimal sequencing, dosing, and patient selection when both drug types are on the table.
Gaps in the evidence and what patients should watch for next
Several important questions remain open. The non-diabetic CKD trial measured eGFR slope as its primary endpoint, not hard clinical outcomes such as progression to dialysis, kidney transplantation, or cardiovascular death. Although eGFR slope is increasingly accepted as a surrogate, regulators and guideline panels will scrutinize whether the magnitude of change is large enough to be clinically meaningful and whether the secondary outcomes align with that signal. Longer-term follow-up and pooled analyses across trials may be needed to clarify the drug’s impact on irreversible endpoints.
Safety will also be central to regulatory review. Finerenone has consistently been associated with higher rates of hyperkalemia compared with placebo, particularly in patients with advanced CKD or those taking other potassium-raising medications. In non-diabetic populations, where baseline risk factors and co-medications may differ from patients with diabetes, it will be critical to understand whether the safety profile shifts. Clinicians will want clear guidance on how often to monitor potassium, how quickly to uptitrate doses, and when to pause or discontinue therapy in the face of rising levels.
For patients, the immediate implications are more about horizon scanning than sudden change. Until regulatory agencies formally extend finerenone’s indication, access for non-diabetic CKD will likely be limited to off-label use, which may not be covered by insurers. Professional societies will review the data and update guidelines, a process that can take months but often shapes how quickly new therapies reach routine practice. In the meantime, nephrologists may begin discussing finerenone as a potential option for selected high-risk patients, especially those with substantial albuminuria despite optimized standard care.
Patients living with CKD can use this moment as an opportunity to revisit their treatment plans. Key questions to ask clinicians include whether current medications already include an SGLT2 inhibitor, whether blood pressure and albuminuria are well controlled, and whether additional therapies like finerenone might eventually be appropriate based on kidney function, potassium levels, and underlying disease cause. As more data emerge on combinations of mineralocorticoid receptor antagonists and SGLT2 inhibitors, shared decision-making will become even more important, balancing incremental benefits against added monitoring and potential side effects.
The broader story is that CKD, long overshadowed by more visible chronic diseases, is finally attracting a wave of targeted therapies. Finerenone’s move beyond diabetes is one step in that evolution. If future research confirms meaningful benefits on kidney failure and survival, and if safety concerns can be managed with careful monitoring, the drug could help close a major treatment gap for the millions of people whose kidneys are failing for reasons other than diabetes.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
